Ключевые слова
Как цитировать
Аннотация
Учитывая возрастающее количество показаний для иммунотерапии, и, соответственно, частоту применения чек-поинт ингибиторов в клинической практике, а также фармакоэкономические аспекты, частоту возникновения и степень тяжести токсичности, возникает необходимость в использовании прогностических и предиктивных маркеров токсичности. В представленном обзоре суммированы данные литературы научных баз PubMed, MEDLINE, Google Scholar, Springer. Для поиска информации были использованы следующие ключевые слова: «предикторы токсичности», «иммунотерапия», «предикторы иммуноопосредованных явлений». Согласно проведенному анализу были выявлены клинические предиктивные маркеры (тип терапии и схему лечения), лабораторные показатели (генотипы HLA-DRB1/DQ1, высокое число лимфоцитов или низкий уровень соотношения нейтрофилов и лимфоцитов, высокое число эозинофилов, высокий уровень IL-17, низкие концентрации IL-10, IL-6, появление различных аутоантител), а также микробиологические маркеры (нарушение состава микрофлоры с увеличением количества представителей Firmicutes).
Библиографические ссылки
Azoury S, Straughan D, Shukla V. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety // Curr Cancer Drug Targets. 2015;15(6):452–62.
Kumar V, Chaudhary N, Garg M et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy // Frontiers in Pharmacology. 2017;8:49.
Nishino M, Sholl LM, Hodi FS. Anti-PD-1-related pneumonitis during cancer immunotherapy // New England Journal of Medicine. 2015;373(3):288–290.
Wang DY, Salem JE, Cohen JV et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis // JAMA Oncol. 2018;4(12):1721–8.
Jiang Y, Zhang N, Pang H et al. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: A systematic review and meta-analysis // Ther Clin Risk Manag. 2019;15:293–302.
Johnson DB, Sullivan RJ, Ott PA et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders // JAMA Oncology. 2016;2(2):234-40.
Boland P, Pavlick AC, Weber J, Sandigursky S. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity // Journal for ImmunoTherapy of Cancer. 2020;8(1):e000356.
Watad A, Bragazzi NL, McGonagle D et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases // Clin Immunol. 2019;203:1–8.
Cutolo M, Capellino S, Sulli A et al. Estrogens and autoimmune diseases // Annals of the New York Academy of Sciences. 2006;1089:538-47.
Invernizzi P, Pasini S, Selmi C et al. Female predominance and X chromosome defects in autoimmune diseases // Journal of Autoimmunity. 2009;33(1):12-6.
Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production // J Clin Invest. 1996;97(9):2063–2073.
Valpione S, Pasquali S, Campana LG et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade // J Transl Med. 2018;16(1):94.
Cortellini A, Buti S, Santini D et al. Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study // Oncologist. 2019;24(6):e327–37.
Faje AT, Sullivan R, Lawrence D et al. Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma // Journal of Clinical Endocrinology and Metabolism. 2014;99(11):4078-85.
Hasan Ali O, Berner F, Bomze D et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors // Eur J Cancer. 2019;107:8–14.
Bluestone JA, Anderson M, Herold KC et al. Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors // Diabetes. 2018;67(8):1471-1480.
Diehl A, Yarchoan M, Hopkins A et al. Relationships between lymphocyte counts and treatmentrelated toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors // Oncotarget. 2017;8(69):114268–80.
Eun Y, Kim IY, Sun JM et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab // Sci Rep. 2019;9(1):14039.
Fujisawa Y, Yoshino K, Otsuka A et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab // J Dermatol Sci. 2017;88(2):225–31.
Apte RN, Krelin Y, Song X et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions // Eur J Cancer. 2006;42(6):751–9.
He QF, Xu Y, Li J et al. CD81 T-cell exhaustion in cancer: Mechanisms and new area for cancer immunotherapy // Brief Funct Genomics. 2019;18(2):99–106.
Nakamura Y, Tanaka R, Maruyama H et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies // Jpn J Clin Oncol. 2019;49(5):431–7.
Schindler K, Harmankaya K, Kuk D et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab // J Clin Oncol. 2014;49(5):431–7.
Shi VJ, Rodic N, Gettinger S et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy // JAMA Dermatology. 2016;152(10):1128–36.
Jaber SH, Cowen EW, Haworth LR et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent // Archives of Dermatology. 2006;142(2):166-72.
Reuben JM, Lee BN, Li C et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma // Cancer. 2006;106(11):2437–44.
Mannino MH, Zhu Z, Xiao H et al. The paradoxical role of IL-10 in immunity and cancer // Cancer Letters. 2015;367(2):103-7.
Tarhini AA, Zahoor H, Lin Y et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma // J Immunother Cancer. 2015;3:39.
Chaput N, Lepage P, Coutzac C et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab // Ann Oncol. 2017;28(6):1368–79.
Tanaka R, Okiyama N, Okune M et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity // Journal of Dermatological Science. 2017;86(1):71-73.
Grivennikov SI, Greten FR KM. Immunity, inflammation, and cancer // Cell. 2010;140(6):883–899.
Liu J, Blake SJ, Harjunpää H et al. Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer // Cancer Res. 2016;76(18):5288–301.
Yoneshima Y, Tanaka K, Shiraishi Y et al. Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies // Lung Cancer. 2019;130:5–9.
Giannicola R, D’arrigo G, Botta C et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab // Mol Clin Oncol. 2019;11(1):81–90.
Tahir SA, Gao J, Miura Y et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities // Proc Natl Acad Sci USA. 2019;116(44):22246–51.
Myers G. Immune-related adverse events of immune checkpoint inhibitors: A brief review // Curr Oncol. 2018;25(5):342–7.
Head L, Gorden N, Van Gulick R et al. Biomarkers to predict immune-related adverse events with checkpoint inhibitors // J Clin Oncol. 2019;37(8_suppl):131–131.
Kimbara S, Fujiwara Y, Iwama S et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab // Cancer Sci. 2018;109(11):3583–90.
Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance // Cell. 2016;165(2):276-87.
Dubin K, Callahan MK, Ren B et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis // Nat Commun. 2016;7:10391.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2021